<DOC>
	<DOCNO>NCT02545465</DOCNO>
	<brief_summary>The aim study understand treatment pattern patient Pulmonary Arterial Hypertension ( PAH ) Chronic Thromboembolic Pulmonary Hypertension ( CTEPH ) switch treatment Adempas real-life clinical practice . In addition , study describe patient demographic reason switch</brief_summary>
	<brief_title>A Study Understand Treatment Patterns Patients With Pulmonary Arterial Hypertension Chronic Thromboembolic Pulmonary Hypertension During Switch Treatment Adempas Real-life Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Female male adult patient diagnose PAH inoperable/recurrent/persistent CTEPH switch PH treatment ( i.e . Endothelin Receptor Antagonist ( ERAs ) , Phosphodiesterase5 inhibitor ( PDE5i ) Prostacyclin Analog ( PCA ) Adempas Patients participate investigational program intervention outside routine clinical practice Patients switch therapy Endothelin Receptor Antagonist ( ERA ) Prostacyclin Analog ( PCA ) receive Adempas purely addon therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Inoperable Chronic Thromboembolic Pulmonary Hypertension</keyword>
	<keyword>Persistent Chronic Thromboembolic Pulmonary Hypertension</keyword>
	<keyword>Recurrent Chronic Thromboembolic Pulmonary Hypertension</keyword>
	<keyword>Switch therapy</keyword>
	<keyword>Titration phase</keyword>
	<keyword>Retrospective chart review</keyword>
</DOC>